Your browser doesn't support javascript.
loading
Physicians' Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey.
Dhruva, Sanket S; Kesselheim, Aaron S; Woloshin, Steven; Ji, Robin Z; Lu, Zhigang; Darrow, Jonathan J; Redberg, Rita F.
Afiliação
  • Dhruva SS; Sanket S. Dhruva (sanket.dhruva@ucsf.edu), University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California.
  • Kesselheim AS; Aaron S. Kesselheim, Brigham and Women's Hospital and Harvard University, Boston, Massachusetts.
  • Woloshin S; Steven Woloshin, Dartmouth College, Lebanon, New Hampshire.
  • Ji RZ; Robin Z. Ji, University of California San Francisco.
  • Lu Z; Zhigang Lu, Brigham and Women's Hospital and Harvard University.
  • Darrow JJ; Jonathan J. Darrow, Brigham and Women's Hospital and Harvard University.
  • Redberg RF; Rita F. Redberg, University of California San Francisco.
Health Aff (Millwood) ; 43(1): 27-35, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38190596
ABSTRACT
Physicians' knowledge of Food and Drug Administration (FDA) approval processes is important in informing clinical decisions and patient discussions. Among a randomly selected national sample of 509 internists, cardiologists, and oncologists, 41 percent reported moderate or better understanding of the FDA's drug approval process, and 17 percent reported moderate or better understanding of the FDA's medical device approval process. Nearly all physicians thought that randomized, blinded trials that met primary endpoints should be very important factors required to secure regulatory approval. Also, nearly all physicians thought that the FDA should revoke approval for accelerated-approval drugs or breakthrough devices that did not show benefit in postapproval studies. Our findings suggest that physicians commonly lack familiarity with drug and medical device regulatory practices and are under the impression that the data supporting FDA drug and high-risk device approvals are more rigorous than they often are. Physicians would value more rigorous premarket evidence, as well as regulatory action for drugs and devices that do not demonstrate safety and effectiveness in the postmarket setting.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Médicos / Oncologistas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Health Aff (Millwood) Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Médicos / Oncologistas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Health Aff (Millwood) Ano de publicação: 2024 Tipo de documento: Article